Toboroz
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Még nem toboroz
AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation
NCT07604727· University Medical Center Groningen· Forrás
Contact: Wouter Wieringa, MD
Még nem toboroz
SVF-Treo Study: Influence of Cardiac and Respiratory Pulsatility Deformation
NCT07475260· University of Twente· Forrás
Contact: Jan Willem Hinnen
Toboroz
NO Re-excision MelanomA - NORMA 2
NCT07530887· 3. fázis· Marieke Goodijk· Forrás
Contact: M. (Maud) Bessems
Toboroz
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
NCT07680335· Alzheimercentrum Amsterdam· Forrás
Contact: A van Strien, MD PhD
Fut, nem toboroz
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024-510965-41-00· 3. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
NCT06220032· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Spinal Cord Monitoring in Multiple Sclerosis
NCT06827834· Zuyderland Medisch Centrum· Forrás
Contact: Jeroen van Eijk
Fut, nem toboroz
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633· 4. fázis· Rijnstate Hospital· Forrás
Toboroz
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06275958· 3. fázis· Leiden University Medical Center· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409· 1/2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
PEHAB II
2023-507466-40-00· 4. fázis· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm
NCT05779631· Radboud University Medical Center· Forrás
Contact: A. G. van der Heijden, Dr.
Toboroz
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583· 3. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: van Veggel B.A.M.H. (Bianca)
Fut, nem toboroz
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973· Terumo Europe N.V.· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)
NCT05704205· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Forrás
Fut, nem toboroz
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· 3. fázis· Genmab· Forrás
Toboroz
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
NCT05326620· PROspective Renal Cancer Cohort Foundation· Forrás
Contact: T Smilde
Fut, nem toboroz
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
NCT05600127· 2. fázis· Erasmus Medical Center· Forrás
Contact: Smilde
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Fut, nem toboroz
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
NCT05392608· 2. fázis· Borstkanker Onderzoek Groep· Forrás
Fut, nem toboroz
LEGACY
NCT05125276· 4. fázis· Amsterdam UMC· Forrás
Fut, nem toboroz
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
NCT04825743· 3. fázis· CeleCor Therapeutics· Forrás
Toboroz
Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome
NCT04754672· Radboud University Medical Center· Forrás
Contact: M. Wumkes, MD
Fut, nem toboroz
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· 3. fázis· German CLL Study Group· Forrás
Toboroz
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
NCT04523428· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Induction Chemotherapy for Locally Recurrent Rectal Cancer
NCT04389086· 3. fázis· Catharina Ziekenhuis Eindhoven· Forrás
Toboroz
Randomised Evaluation of COVID-19 Therapy
NCT04381936· 3. fázis· University of Oxford· Forrás
Toboroz
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
NCT06434896· UMC Utrecht· Forrás
Contact: M.L. Wumkes
Fut, nem toboroz
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
NCT04097470· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
NCT03764553· 2. fázis· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Forrás
Meghívásos bevonás
Prospective Registry on Intravascular Lithotripsy
NCT06577038· Leiden University Medical Center· Forrás
Fut, nem toboroz
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261· 3. fázis· Acerta Pharma BV· Forrás
Fut, nem toboroz
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
NCT03673826· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
NCT03463057· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
NCT03620578· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)· Forrás
Fut, nem toboroz
FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease
NCT03562572· Zuyderland Medisch Centrum· Forrás
Showing 50 of 56.